[12] Patent
[11] Patent No.:GC0007591  
[45] Date of Publishing the Grant of the Patent: 30/Apr /2018                48/2018  
Number of the Decision to Grant the Patent:2018/126043
Date of the Decision to Grant the Patent:16/Apr/2018

[21] Application No.:GC 2011-19652

[22] Filing Date:30/10/2011

[30] Priority:

[33] State [32] Priority date [31] Priority No.
US
US
US
US
4/11/2010
10/11/2010
11/11/2010
3/3/2011
61/410,158
61/411,953
61/412,594
61/448,785

[72] Inventors:1- Rachel Rebecca BARRETT،2- Keith CANADA،3- Katrina Mary CATRON،4- Robert COPENHAVER،5- Lee Edward FREGO،6- Ernest Lee RAYMOND،7- Sanjaya SINGH،8- Xiangyang ZHU

[73] Owner: BOEHRINGER INGELHEIM INTERNATIONAL GMBH, Binger Strasse 173, 55216 , Ingelheim am Rhein, Germany

[74] Agent: Saba & Co. T.M.P

  

 

  

[51]IPC:
Int. Cl.7: [C07K16/24]

[56] Cited Documents:

-WO 2007027714 A2 (SCHERING CORP [US]; PRESTA LEONARD G [US]) 8 March 2007
-WO 2007005955 A2 (CENTOCOR INC [US]; BENSON JACQUELINE [US]; CUNNINGHAM MARK [US]; DUCHA) 11 January 2007
-WO 2007024846 A2 (LILLY co ELI [US]; BEIDLER CATHERINE BRAUTIGAM [US]; BRIGHT STUART WI L) 1 March 2007
 
Examiner: PH. Sultana K. AlOudah

[54] ANTI-IL-23 ANTIBODIES
[57] Abstract: The present invention relates to anti-IL-23p19 binding compounds, in particular new humanized anti-IL-23p19 antibodies and therapeutic and diagnostic methods and compositions for using the same.
No. of claims: 26     No. of figures: 2


 

Note: Any interested individual may, within 3 months of publication of the grant, file objection thereof with the Grievance Committee after payment of grievance fees.